Pharmacotherapy of addictive disorders

Clinical Neuropharmacology

Volumn 32, Issue 5, 2009, Pages 277-289

  Ross, Stephen ^a,b,c   Peselow, Eric ^b  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Neurobiology; Pharmacotherapy

Indexed keywords

ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; BACLOFEN; BP 897; BROMOCRIPTINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; COCAINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DISULFIRAM; IBOGAINE; METHADONE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; OXYCODONE; RIMONABANT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; XENOVA;

ABDOMINAL PAIN; ACCIDENT; ADDICTION; AGITATION; ALCOHOLISM; ANXIETY DISORDER; BEHAVIOR CHANGE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONSTIPATION; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; HEADACHE; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HUMAN; INJURY; INSOMNIA; LIVER CELL DAMAGE; LOW DRUG DOSE; MENTAL DISEASE; MORPHINE ADDICTION; MOTOR DYSFUNCTION; MUSCLE SPASM; NAUSEA; NEUROLOGIC DISEASE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OBESITY; OPIATE ADDICTION; ORGASM DISORDER; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SWEATING; TOBACCO DEPENDENCE; TORSADE DES POINTES; URINE RETENTION; VACCINATION; VISUAL DISORDER; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ALCOHOL DETERRENTS; ANIMALS; BEHAVIOR, ADDICTIVE; BUPROPION; DOPAMINE AGENTS; HUMANS; NALTREXONE; SUBSTANCE-RELATED DISORDERS;

EID: 70349820514     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181a91655     Document Type: Review

References (168)

1. SAMHSA (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings. (DHHS Publication no. SMA 07-4293, NSDUR series H-32) Office of Applied Studies: Rockville, MD.
2. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adultsVUnited States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:1157-1161.
3. Volkow ND, Li TK. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther 2005;108:3-17.
4. Ross S, Collins E, Galanter M. Substance Use Disorders in the Medically Ill, in Psychosomatic Medicine. In: Blumenfield M, Strain JJ, eds. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 461-492.
5. Ewing GB, Selassie AW, Lopez CH, et al. Self-report of delivery of clinical preventive services by U.S. physicians. Comparing specialty, gender, age, setting of practice, and area of practice. Am j Prev Med 1999;17(1):62-72.
6. Fleming MF, Barry KL. The effectiveness of alcoholism screening in an ambulatory care setting. J Stud Alcohol 1991;52:33-36.
7. McLellan AT, Meyers K. Contemporary addiction treatment:A review of systems problems for adults and adolescents. Biol Psychiatry 2004;56:764-770.
8. Drucker E, Nadelmann E, Newman RC, et al. Harm reduction: pragmatic drug policies for public health and safety. In: Lowinson JH, Ruiz P, Millman RB, et al, eds. Substance Abuse:A Comprehensive Textbook. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 1229-1250.
9. Saitz R, Larson MJ, LaBelle C, et al. The case for chronic disease management for addiction. J Addict Med 2008;2(2):55-65.
10. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284(4):1689-1695.
11. Vocci F, Ling W. Medications development: successes and challenges. Pharmacol Ther 2005;108:94-108.
12. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signaling. Trends Pharmacol Sci 2004;25: 317-324.
13. Tapper AR, Mekinne SL, Nashmi R, et al. Nicotine activation of >4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004;306:1029-1032.
14. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001;70:439-446.
15. Benowitz NL. Neurobiology of nicotine addiction:Implications for smoking cessation treatment. Am J Med 2008;121(4A):S3YS10.
16. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005;55:281-299.
17. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008;121(4A):S20YS31.
18. West R, Hajek P, Foulds J, et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 2000;149:198-202.
19. Slemmer JE, Marti BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-327.
20. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;(4):CD000031.
21. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs 2002;62(suppl 2):25-35.
22. Coe JW, Brooks PR, Wirtz MC, et al. 3,5-Bicyclic aryl piperidines:A novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett 2005;15:4889-4897.
23. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an >4A2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation:A randomized controlled trial. JAMA 2006;296:47-55.
24. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an >4A2 vs placebo or sustained-release bupropion for smoking cessation:A randomized controlled trial. JAMA 2006;296:56-63.
25. US Food and Drug Administration. Public Health Advisory:Important Information on Chantix (varenicline). US Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/cder/drug/ advisory/varenicline.htm. Accessed February 1, 2008.
26. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation:A review. Nicotine Tob Res 2005;7:491-499.
27. Hall SM, Reus VI, Muños RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-690.
28. Koob GF. Neurobiology of Addiction. In Textbook of Substance Abuse Treatment. 4th ed. Galanter M, Kleber HD, eds. Washington, DC:American Psychiatric Publishing, Inc.; 2008:3-16.
29. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
30. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000058.
31. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000146. Further research to see if there is an enhanced treatment effect with bupropion and varenicline.
32. Colombo G, Serra S, Vacca G, et al. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav 2005;81:369-380.
33. Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005;81: 387-395.
34. Reynolds J, Campbell RK. Emerging treatment for diabetes, obesity, and smoking. US Pharmacist 2005;11:75-79.
35. Rimonabant regulatory update in the United States. Paris: sanofi-aventis. Available at: http://en.sanofi-aventis.com/press/ppc-18223.asp. Accessed June 29, 2007.
36. Kosten T, Owens MS. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005;108:76-85.
37. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005;78:456-467.
38. Vengeliene V, Bilbao A, Molander A, et al. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008;154:299-315.
39. Littleton JM. Acamprosate in alcohol dependence:Implications of a unique mechanism of action. J Addict Med 2007;1(3):115-125.
40. Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 2007;21:9-28.
41. Johnson BA, Ait Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics:From hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000;24(5):737-742.
42. Hoffman PL, Rabe CS, Grant KA, et al. Ethanol and the NMDA receptor. Alcohol 1990;7:229-231.
43. Tsai GE, Ragan P, Chang R, et al. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998;155:726-732. (Pubitemid 28252650)
44. Krystal JH, Petrakis IL, Krupitsky E, et al. NMDA receptor antagonism and the ethanol intoxication signal:From alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 2003;1003:176-184.
45. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram. A half century later. J Clin Psychopharmacol 2006;26(3):290-302.
46. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004;99:21-24.
47. Banys P. The clinical use of disulfiram (Antabuse):A review. J Psychoactive Drugs 1988;20:243-260.
48. Lundwall L, Baekeland F. Disulfiram treatment of alcoholism. J Nerv Ment Dis 1971;153(6):381-394.
49. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence. A review of the evidence. JAMA 1999;281: 1318-1325.
50. Mottin JL. Drug-induced attenuation of alcohol consumption:A review and evaluation of the claimed, potential or current therapies. Q J Stud Alcohol 1973;34:444-472.
51. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. AVeterans Administration cooperative study. JAMA 1986;256(11):1449-1455.
52. Brewer C, Meyers RJ, Johnson J. Does disulfiram help to prevent relapse in alcohol abuse? CNS drugs 2000;14:329-341.
53. Gerrein JR, Rosenberg CM, Manohar V. Disulfiram maintenance in outpatient treatment of alcoholism. Arch Gen Psychiatry 1973;28: 799-802.
54. Azrin NH. Improvements in community-reinforcement approach to alcoholism. Behav Res Ther 1976;14:339-348.
55. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992;161:84-89.
56. Buonopane A, Petrakis IL. Pharmacotherapy of alcohol use disorders. Substance Use Misuse 2005;40:2001-2020.
57. O-Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence:A controlled study. Arch Gen Psychiatry 1992;49:881-887.
58. Volpicelli JR, Alterman AI, Hayishada M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880.
59. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence:A review of the evidence. JAMA 1999;281: 1318-1325.
60. Streeton C, Whelan G. Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence:A meta-analysis of randomized controlled trials. Alcohol Alcohol 2001;36:544-552.
61. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment:A meta-analysis. Alcohol Clin Exp Res 2001;25:1335-1341.
62. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005;(1):CD001867.
63. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001;36:2-10.
64. Pettinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Current Psychiatry Reports 2006;8:383-388.
65. Oslin DW, Berrettini WH, O-Brien CP. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol 2006;11(3-4):397- 403.
66. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 2005;293:1617-1625.
67. Dean RL. The preclinical development of Medisorb naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci 2005;10:643-655.
68. Pettinati HM, Volpicell JR, Pierce JD, et al. Improving naltrexone response:An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000;19(1):71-83.
69. June HL, Grey C, Warren-Reese C, et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 1998;22: 2174-2185.
70. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol Clin Exp Res 1994;18:1162-1167.
71. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56:719-724.
72. Bachteler D, Economidou D, Danysz W, et al. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 2005;30: 1104-1110.
73. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal:A double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36:413-418.
74. Hopkins JS, Garbutt JC, Poole CL, et al. Naltrexone and acamprosate: meta-analysis of two medical treatments for alcoholism. Alcohol Clin Exp Res 2002;26:130A.
75. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence:An evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13:469-475.
76. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study:A randomized controlled trial. JAMA 2006;295:2003-2017.
77. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40:383-393.
78. Addolorato G, Caputo F, Capristo E, et al. Ability of baclofen in reducing alcohol craving and intake:IIVPreliminary clinical evidence. Alcohol Clin Exp Res 2000;24:67-71. (Pubitemid 30062783)
79. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence:A preliminary open-label study. Alcohol Clin Exp Res 2004;28:1517-1523.
80. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake:A preliminary double-blind randomized controlled study. Alcohol Alcohol 2002;37:504-508.
81. Johnson BA. Recent advances in the development of treatment for alcohol and cocaine dependence:Focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005;19(10): 873-896.
82. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence:A randomized controlled trial. Lancet 2003;361(9370):1677- 1685.
83. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence:A randomized controlled trial. JAMA 2007;298(14):1641-1651.
84. Mann K. Pharmacotherapy of alcohol dependence. A review of the clinical data. CNS Drugs 2004;18(8):485-504.
85. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994;18:879-885.
86. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients:A randomized clinical trial. JAMA 2000;284:1016-1017.
87. Landabaso MA, Iraurgi I, Sanz J, et al. Naltrexone in the treatment of alcoholism. Two-year follow results. Eur J Psychiatry 1999; 13(2):97-105.
88. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism:A controlled study. Alcohol Clin Exp Res 1998;22:573-579.
89. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism:A double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-99.
90. Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence:A single centres- experience with pharmacotherapy. Alcohol Alcohol 2006;41:321-327.
91. Grant JE, Brewer JA, Potenza MN. The neurobiology of substance and behavioral addictions. CNS Spectr 2006;11(12):924-930.
92. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214-226.
93. Hser YI, Hoffman V, Grella CE, et al. A 33-year follow-up of narcotics. Arch Gen Psychiatry 2001;58:503-508.
94. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-470.
95. Kreek MJ. Medical complications in methadone patients. Ann N Y Acad Sci 1978;311:110-134.
96. Marmor M, Penn A, Widmer K, et al. Coronary artery disease and opioid use. Am J Cardiol 2004;93(10):1295-1297.
97. Dart R, Woody G, Kleber H. Prescribing methadone as an analgesic. Ann Intern Med 2005;143:620.
98. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137:501-504.
99. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
100. McLellan AT, Arndt IO, Metzqer DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269:1953-1959.
101. Farré M, Mas A, Torrens M, et al. Retention rate and illicit opioid use during methadone maintenance interventions:A meta-analysis. Drug Alcohol Depend 2002;65:283-290.
102. Donny EC, Walsh SL, Biqelow GE, et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 2002;161:202-212.
103. Kintz P. Deaths involving buprenorphine:A compendium of French cases. Forensic Sci Int 2001;121:65-69.
104. Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict 2003;12:S5YS18.
105. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267(20):2750-2755.
106. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence:A multicenter, randomized clinical trial. Addiction 1998;93(4):475-486.
107. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;CD00207.
108. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts:A double-blind, double-dummy comparison study. Addiction 2006;101:275-281.
109. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006;82:250-257.
110. Heidbreder C. Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol 2005;526:101-112. (Pubitemid 41744109)
111. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35(3): 192-213.
112. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006;(1):CD001333.
113. Preston KL, Silverman K, Umbricht A, et al. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999;54(2):127-135.
114. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professional. J Subst Abuse Treat 1997;14:19-22.
115. Lobmaier P, Kornør H, Kunøe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD006140.
116. Glick SD, Maisonneuve IM. Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci 2000;909:88-103.
117. Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 2000;914:394-401.
118. Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 1998;844:274-292.
119. Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999;8:234-242.
120. Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 1994;11: 379-385.
121. Molinari HH, Maisonneuve IM, Glick SD. Ibogaine neurotoxicity:A re-evaluation. Brain Res 1996;737(1-2):255-262.
122. Alper KR. Ibogaine:A review. Alkaloids Chem Biol 2001;56:249-281.
123. Maas U, Strubelt S. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses 2006;67(4):960-964.
124. Maissoneuve IM, Glick SD. Anti-addictive actions of an iboga alkaloid congener:A novel mechanism for a novel treatment. Pharmacol Biochem Behav 2003;75(3):607-618.
125. Kalivas PW. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007;9(4):389-397.
126. Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993;60:527-535.
127. Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine (NAT) and serotonin transporters (SAT):A structure-activity study. Life Sci 1990;46:635-645.
128. Rocha BA, Fumaqalli F, Gainetdinov RR, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998;1:132-137.
129. Rocha BA. Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol 2003;479:107-115.
130. van den Brink W, van Ree JM. Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 2003;13: 476-487. (Pubitemid 37433968)
131. Matecka D, Rothman RB, Radesca L, et al. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-(2-(diphenylmethoxy)ethyl)-and 1-(2-(bis(4-fluorophenyl) methoxy)ethyl)-4-(3-phenylpropyl) piperazines (GBR 12935 and GBR 12909). J Med Chem 1996;39: 4704-4716.
132. Anderson PH. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 1989;166: 493-504.
133. Shiosaki K, Asin KE, Britton DR, et al. Hyperactivity and behavioural seizures in rodents following treatment with dopamine D1 receptor agonist A-86929 and ABT-431. Eur J Pharmacol 1996;317:183-190.
134. Shoptaw S, Kintaudi PC, Charuvastra C, et al. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend 2002;66(3):217-224.
135. Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propanolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006; 85:129-137.
136. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment:A double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-526.
137. Shearer J, et al. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98: 1137-1141.
138. Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007;12:133-151.
139. Pilla M, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999;400:371-375.
140. Brown ES, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66:756-760.
141. Beresford TP, et al. Aripiprazole in schizophrenia with cocaine dependence:A pilot study. J Clin Psychopharmacol 2005;25:363-366.
142. Regier DA, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-2518.
143. Higgins ST, et al. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993;150(4):675-676.
144. Carroll KM, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93:713-728.
145. Carroll KM, et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 2000;95:1335-1349.
146. Petrakis IL, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000;95(2):219-228.
147. Carroll K, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients:A randomized placebo-controlled trial. Arch Gen Psychiatry 2004;61(3):264-272.
148. McCance-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration:Initial results. Biol Psychiatry 1998;43:540-543.
149. Cubells JF, et al. DBH genotype in disulfiram treatment for cocaine dependence. Neuropsychopharmacology 2004;29(suppl 1):S72.
150. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 1993;18(1):75-113.
151. Brebner K, et al. The GABA (B) agonist CGP44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology 1999; 8:1797-1804.
152. Gorelick DA, Gardner EL, Zheng-Xiong X. Agents in development for the management of cocaine abuse. Drugs 2004;64(14):1547-1573.
153. Brebner K, Childress AR, Roberts DS. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002;37:478-484.
154. Shoptaw S, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64:1440-1448.
155. Winhusen TM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100:68-77.
156. Gonzalez G, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003;98:1625-1632.
157. Gonzalez G, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine-dependent methadone-treated patients. Drug Alcohol Depend 2007;87:1-9.
158. Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction:From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003;50:261-265.
159. Brodie JD, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005;55:122-125.
160. Kampman KM, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004b;75:233-240.
161. de Lima MS, de Oliveira Soares BG, Reisser AA, et al. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003;2: CD002950.
162. Johnson BA. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006; 84:256-263.
163. LaRowe S, et al. Cocaine desire is reduced by N-acetylcysteine. Am J Psychiatry 2007;164:1115-1117.
164. Peters J, Kalivas PW. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 2006;186:143-149.
165. Ferraro L, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20: 346-356.
166. Dackis CA. Recent advances in the pharmacotherapy of cocaine dependence. Curr Psychiatry Rep 2004;6:323-331.
167. Dackis CA, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30: 205-211.
168. Martell BA, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58:158-164.